Refractory, primary Central Nervous System Neoplasm Active Not Recruiting Phase 1 Trials for Selinexor (DB11942)

Back to Refractory, primary Central Nervous System Neoplasm

Also known as: Refractory Primary Central Nervous System Neoplasm

IndicationStatusPhase
DBCOND0142769 (Refractory, primary Central Nervous System Neoplasm)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02323880Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade GliomasTreatment